birb 796 has been researched along with lipoteichoic acid in 2 studies
| Studies (birb 796) | Trials (birb 796) | Recent Studies (post-2010) (birb 796) | Studies (lipoteichoic acid) | Trials (lipoteichoic acid) | Recent Studies (post-2010) (lipoteichoic acid) |
|---|---|---|---|---|---|
| 137 | 5 | 80 | 1,625 | 12 | 646 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoogendijk, AJ; Pinhanços, SS; van der Poll, T; Wieland, CW | 1 |
| Bailey, SR; Bauquier, JR; Tennent-Brown, BS; Tudor, E | 1 |
2 other study(ies) available for birb 796 and lipoteichoic acid
| Article | Year |
|---|---|
Intrapulmonary administration of a p38 mitogen activated protein kinase inhibitor partially prevents pulmonary inflammation.
Topics: Animals; Cell Line; Cytokines; Female; Humans; Immunoglobulin M; Lipopolysaccharides; Macrophages, Alveolar; Male; Mice; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pneumonia; Protein Kinase Inhibitors; Pulmonary Alveoli; Pyrazoles; Teichoic Acids | 2013 |
Anti-inflammatory effects of a p38 MAP kinase inhibitor, doramapimod, against bacterial cell wall toxins in equine whole blood.
Topics: Animals; Anti-Inflammatory Agents; Bacterial Toxins; Biological Assay; Cell Line; Horses; Interleukin-1beta; Lipopolysaccharides; Mice; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Peptidoglycan; Pyrazoles; Signal Transduction; Teichoic Acids; Tumor Necrosis Factor-alpha | 2020 |